**Supplemental Digital Content 2- Table 2.** The number and incidence of IPD cases per PCV7 and PCV13 serotype from children < 16 years of age, 2007-08 to 2017-18

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Type | 2007-08 | 2008-09 | 2009-10 | 2010-11 | 2011-12 | 2012-13 | 2013-14 | 2014-15 | 2015-16 | 2016-17 | 2017-18 | IRR | 95%CI | P value |
| n | IR | n | IR | n | IR | n | IR | n | IR | n | IR | n | IR | n | IR | n | IR | n | IR | n | IR |
| **PCV7** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 4 | 4 | 0.42 | 2 | 0.21 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | - | 0.01-1.82 | 0.1189 |
| 14 | 18 | 1.91 | 12 | 1.24 | 2 | 0.20 | 0 | 0.00 | 1 | 0.10 | 0 | 0.00 | 1 | 0.09 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | - | 0.00-0.39 | 0.0091 |
| 18C | 8 | 0.85 | 3 | 0.31 | 6 | 0.61 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | - | 0.00-0.90 | 0.0419 |
| 19F | 3 | 0.32 | 6 | 0.62 | 0 | 0.00 | 3 | 0.30 | 2 | 0.19 | 3 | 0.29 | 0 | 0.00 | 1 | 0.09 | 0 | 0.00 | 2 | 0.19 | 2 | 0.19 | 0.59 | 0.10-3.51 | 0.5595 |
| 23F | 5 | 0.53 | 5 | 0.52 | 1 | 0.10 | 2 | 0.20 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 0.09 | 0 | 0.00 | - | 0.00-1.45 | 0.0873 |
| 6B | 7 | 0.74 | 6 | 0.62 | 3 | 0.30 | 3 | 0.30 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 0.09 | 0.13 | 0.02-1.02 | 0.0525 |
| 9V | 5 | 0.53 | 4 | 0.41 | 2 | 0.20 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | - | 0.00-1.45 | 0.0873 |
| **PCV13** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 1 | 2 | 0.21 | 3 | 0.31 | 4 | 0.40 | 1 | 0.10 | 1 | 0.10 | 4 | 0.38 | 0 | 0.00 | 1 | 0.09 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | - | 0.01-3.67 | 0.2623 |
| 3 | 1 | 0.11 | 0 | 0.00 | 3 | 0.30 | 1 | 0.10 | 2 | 0.19 | 1 | 0.10 | 2 | 0.19 | 0 | 0.00 | 3 | 0.28 | 1 | 0.09 | 1 | 0.09 | 0.88 | 0.06-14.08 | 0.9283 |
| 19A | 4 | 0.42 | 4 | 0.41 | 4 | 0.40 | 7 | 0.69 | 3 | 0.29 | 10 | 0.96 | 4 | 0.38 | 4 | 0.38 | 7 | 0.66 | 3 | 0.28 | 3 | 0.28 | 0.66 | 0.15-2.95 | 0.5869 |
| 6A | 4 | 0.42 | 2 | 0.21 | 3 | 0.30 | 1 | 0.10 | 1 | 0.10 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | - | 0.01-1.82 | 0.1189 |
| 7F | 6 | 0.64 | 4 | 0.41 | 10 | 1.01 | 6 | 0.59 | 6 | 0.58 | 4 | 0.38 | 3 | 0.28 | 0 | 0.00 | 1 | 0.09 | 1 | 0.09 | 1 | 0.09 | 0.15 | 0.02-1.22 | 0.0756 |

PCV7 and PCV13-7 denote the serotypes in each vaccine-type group as listed. IR denotes the incidence rate of typed isolates per 100,000 population per epidemiological year. n= number of isolates typed per epidemiological year. Incidence Rate Ratio (IRR) denotes the ratio between the incidence rate of typed isolates in the epidemiological year 2017-18 comparison to the pre PCV-vaccine epidemiological year 2007-08. 95% CI denotes the 95% confidence interval of the IRR.